or
forgot password

    • cancer clinical trials in springfield, OR

    • A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
    Willamette Valley Cancer Institute and Research Center
    Springfield, Oregon 97477
    Small Cell Lung Cancer, Non-small Cell Lung Cancer
    Provenge (TM) for the Treatment of Hormone Sensitive Prostate Cancer
    Oregon Urology Institute
    Springfield, Oregon 97477
    Prostate Cancer
    Sunitinib Non Small Cell Lung Cancer Patients Over 70
    Willamette Valley Cancer Institute and Research Center
    Springfield, Oregon 97477
    Non Small Cell Lung Cancer
    A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
    Willamette Valley Cancer Institute and Research Center

    Trial Locations
    Willamette Valley Cancer Institute and Research Center
    Williamette Valley Cancer Institute and Research Center
    Breast Cancer
    Connect® MM- The Multiple Myeloma Disease Registry
    US Oncology - Willamette Valley Cancer Institute - Springfield
    Springfield, Oregon 97477
    Multiple Myeloma
    Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
    Willamette Valley Cancer Institute and Research Center
    Springfield, Oregon 97477
    Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
    An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
    Willamette Valley Cancer Institute and Research Center
    Springfield, Oregon 97477
    Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin, Acute Myeloid Leukemia, Multiple Myeloma
    Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)
    Willamette Valley Cancer Institute and Research Center
    Springfield, Oregon 97477
    Ovarian Cancer
    A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung
    Willamette Valley Cancer Institute and Research Center
    Springfield, Oregon 97477
    Adenocarcinoma of the Lung
    A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
    Oregon Urology Institute
    Springfield, Oregon 97477
    Advanced Prostate Cancer, Prostatic Neoplasms
    Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
    Willamette Valley Cancer Institute and Research Center
    Springfield, Oregon 97477
    Colorectal Cancer
    Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
    US Oncology Research: Willamette Valley Cancer Institute and Research Center
    Springfield, Oregon 97477
    B Cell Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia
    DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
    Oregon Urology Institute
    Springfield, Oregon 97477
    Urothelial Carcinoma
    A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
    Willamette Valley Cancer Institute and Research Center
    Springfield, Oregon 97477
    Non Small Cell Lung Cancer
    SpaceOAR System Pivotal Study
    Oregon Urology Institute
    Springfield, Oregon 97477
    Prostate Cancer
    Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer
    Willamette Valley Cancer Institute and Research Center
    Springfield, Oregon 97477
    Non Small Cell Lung Cancer
    Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
    Oregon Urology Institute
    Springfield, Oregon 97477
    Prostate Cancer
    A Phase 2 of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
    Williamette Valley Cancer Center and Research Institute
    Springfield, Oregon 97477
    Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin's Lymphoma
    Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
    Willametter Valley Cancer Institute
    Springfield, Oregon 97477
    B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Well-differentiated Lymphocytic Lymphoma, B Cell Lymphoma, Follicular Lymphoma,, Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma, Waldenstrom Macroglobulinemia, Burkitt Lymphoma, B-Cell Diffuse Lymphoma
    A Long Term Safety Study With Atrasentan
    Oregon Urology Specialist, Division of Clinical Research
    Springfield, Oregon 97477
    Prostate Cancer, Adenocarcinoma
    TroVax Renal Immunotherapy Survival Trial
    Oregon Urology Institute
    Springfield, Oregon 97477
    Clear Cell Renal Carcinoma
    Assessment and Tracking of Long-term Alefacept Safety
    Eric Olson
    Springfield, Oregon 97477
    Psoriasis
    Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ
    Oregon Urology Institute Research
    Springfield, Oregon 97477
    Urinary Bladder Cancer, Bladder Cancer, Bladder Neoplasms, Bladder Tumors
    Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
    Willamette Valley Cancer Institute and Research Center
    Springfield, Oregon 97477
    Breast Cancer
    Safety of PCI-32765 in Chronic Lymphocytic Leukemia
    Willamette Valley Cancer Institute and Research Center
    Springfield, Oregon 97477
    B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer
    Willamette Valley Cancer Institute and Research Center
    Springfield, Oregon 97477
    Metastatic Pancreatic Cancer
    Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
    Willamette Valley Cancer Institute and Research Center
    Springfield, Oregon 97477
    Anemia, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small-Cell Lung, Bladder Cancer, Cancer of Head and Neck, Uterine Cervical Cancer